Triumeq is dolutegravir, abacavir and lamivudine. Juluca is dolutegravir and rilpivirine.
- TRADE NAMES: Juluca (ViiV); Tivicay (ViiV); Triumeq (ViiV)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Integrase strand transfer inhibitor
- HALF-LIFE: ~14 hours
- FDA APPROVAL DATE: 08/12/2013
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Dofetilide
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dolutegravir in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
